IceCure Medical (NASDAQ:ICCM) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a research note issued to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock.

Separately, Alliance Global Partners boosted their target price on IceCure Medical from $1.90 to $2.90 and gave the stock a buy rating in a research report on Wednesday, March 20th.

IceCure Medical Stock Up 0.9 %

NASDAQ:ICCM opened at $0.74 on Tuesday. IceCure Medical has a 1-year low of $0.52 and a 1-year high of $1.57. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.39 and a quick ratio of 2.88. The company has a market capitalization of $33.82 million, a PE ratio of -2.25 and a beta of 0.57. The firm’s 50-day moving average price is $0.97 and its 200-day moving average price is $1.16.

IceCure Medical (NASDAQ:ICCM) last released its earnings results on Tuesday, May 28th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). The firm had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $0.80 million. IceCure Medical had a negative return on equity of 101.66% and a negative net margin of 444.30%. During the same period in the prior year, the firm posted ($0.08) earnings per share. On average, equities analysts predict that IceCure Medical will post -0.28 EPS for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.